About | TBCRC

About Us

Our Mission

The goal of the TBCRC is to conduct innovative, high impact, biologically-driven translational and clinical research. Our mission is to lessen the burden of breast cancer by using a multidisciplinary approach to discover novel mechanisms of breast cancer pathogenesis and test innovative, basic science-based therapeutic strategies.

Our History

The Translational Breast Cancer Research Consortium (TBCRC) is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of eighteen clinical sites, five core subcommittees/ working groups (WGs) comprised of a Correlative Science WG and four other groups organized around various breast cancer phenotypes (including the Triple Negative WG, the HER2 Resistance WG, the Endocrine Resistance WG, and the Locoregional Disease WG), four interest groups (IGs) including the Radiation Therapy, Patient Reported Outcomes, Immuno-Oncology, and Social Media IGs, the Patient Recruitment Task Force, a patient advocate WG, a study coordinator WG, a contracts/ administrators WG, and a Central Office. Collectively, these groups work together to foster trial development in a collegial environment that enhances cross-institutional collaborations.

Leadership

Central Office

Ian Krop, M.D., Ph.D.

Chief Scientific Officer

Antonio Wolff, M.D.

Chief Operating Officer

Cindy Morin

Business Manager

Robyn Burns, Ph.D.

Program Manager

Executive Committee

Antonio Wolff, M.D.

Johns Hopkins University

Charles (Chuck) Perou, Ph.D.

University of North Carolina at Chapel Hill

Eric Winer, M.D.

Yale University

Fraser Symmans, M.D.

MD Anderson Cancer Center

Ian Krop, M.D., Ph.D.

Yale University

Larry Norton, M.D.

Memorial Sloan Kettering Cancer Center

Lisa Carey, M.D.

University of North Carolina at Chapel Hill

Matthew Goetz, M.D.

Mayo Clinic Cancer Center

Nancy Davidson, M.D.

University of Washington School of Medicine/Fred Hutchinson Cancer Research Center

Shelley Hwang, M.D., M.P.H

Duke University Medical Cancer Center

Susan Hilsenbeck, Ph.D.

Baylor College of Medicine

Tari King, M.D.

Dana-Farber/Harvard Cancer Center

Steering Committee

Adrian Lee, Ph.D.

Duke University Medical Cancer Center

Alice Ho, M.D.

Duke University Medical Cancer Center

Angela DeMichele, M.D.

University of Pennsylvania

Antonio Wolff, M.D.

Johns Hopkins University

Charles (Chuck) Perou, Ph.D.

University of North Carolina at Chapel Hill

Claudine Isaacs, M.D.

Georgetown University

Eric Winer, M.D.

Yale University

Erica Stringer-Reasor, M.D.

University of Alabama at Birmingham Comprehensive Cancer Center

Fraser Symmans, M.D.

MD Anderson Cancer Center

Ian Krop, MD, Ph.D.

Yale University

Jesus Anampa Mesias, M.D.

Montefiore Medical Center

Justin Balko, Pharm.D., Ph.D.

Vanderbilt University

Larry Norton, M.D.

Memorial Sloan Kettering Cancer Center

Lisa Carey, M.D.

University of North Carolina at Chapel Hill

Matthew Goetz, M.D.

Mayo Clinic Cancer Center

Michelle Melisko, M.D.

University of California San Francisco

Nancy Davidson, M.D.

University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Rita Nanda, M.D.

University of Chicago Medical Center

Shelley Hwang, M.D.

Duke University Medical Cancer Center

Susan Hilsenbeck, Ph.D.

Baylor College of Medicine

Tari King, M.D.

Dana-Farber/ Harvard Cancer Center

Subcommittee Chairs

Contracts and Administrators Working Group

Cindy Morin,

Johns Hopkins University

Michelle Sloan,

Johns Hopkins University

Correlative Science Working Group

Adrian Lee, Ph.D.,

University of Pittsburgh

Andrea Richardson, M.D., Ph.D.,

Johns Hopkins University

Endocrine Resistance Working Group

Claudine Isaacs, M.D.,

Georgetown University

Komal Jhaveri, M.D.,

Memorial Sloan Kettering Cancer Center

HER2 Resistance Working Group

Nancy Lin, M.D.,

Dana-Farber/ Harvard Cancer Center

Mothaffar Rimawi, M.D.,

Baylor College of Medicine

Immuno-Oncology Interest Group

Elizabeth Mittendorf, M.D., Ph.D.,

Dana-Farber/ Harvard Cancer Center

Justin Balko, Pharm.D., Ph.D.,

Vanderbilt University

Locoregional Disease Working Group

Alastair Thompson, M.D.,

Baylor College of Medicine

Gaorav Gupta, M.D., Ph.D.,

University of North Carolina at Chapel Hill

Patient Advocate Working Group

Thelma Brown

Jamie LaScala

Patient Recruitment Task Force

Erica Stringer-Reasor, M.D.,

University of Alabama at Birmingham Comprehensive Cancer Center

Cesar Santa Maria, M.D.,

Johns Hopkins University

Pre-Operative Radiation Therapy Interest Group

Gaorav Gupta, M.D., Ph.D.,

University of North Carolina at Chapel Hill

Alice Ho, M.D.,

Duke University Medical Cancer Center

PRO Interest Group

Michelle Melisko, M.D.,

University of California San Francisco

Eileen Shinn, Ph.D.,

MD Anderson Cancer Center

Social Media Interest Group

Meghan Flanagan, M.D.,

University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Puneet Singh, M.D.,

MD Anderson Cancer Center

Statistical Advisory Committee

Elizabeth Garrett-Mayer, Ph.D.,

ASCO

Sue Hilsenbeck, Ph.D.,

Baylor College of Medicine

Study Coordinator Working Group

Jennifer Savoie,

Dana-Farber/ Harvard Cancer Center

Michelle DeMeo,

Dana-Farber/Harvard Cancer Center

Rometa Pollard,

University of Pittsburgh

Amanda Spratt,

University of Chicago Medical Center

Triple Negative Working Group

Jennifer Specht, M.D.,

University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Justin Balko, Pharm.D., Ph.D.,

Vanderbilt University